NCT03595930View on ClinicalTrials.gov

Post-marketing Surveillance (PMS) Study to Observe the Safety and Effectiveness of ARNUITY in Asthma Subjects in a Real World Setting

CompletedOBSERVATIONAL
Enrollment

668

Participants

Timeline

Start Date

September 21, 2018

Primary Completion Date

July 22, 2020

Study Completion Date

July 22, 2020

Conditions
Asthma
Interventions
DRUG

Arnuity

ARNUITY consist of Fluticasone Furoate, is an Inhaled corticosteroids (ICS) medicine taken as one inhalation, once daily, for the control and prevention of asthma in adults and children aged 12 years and older.

Trial Locations (1)

Unknown

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03595930 - Post-marketing Surveillance (PMS) Study to Observe the Safety and Effectiveness of ARNUITY in Asthma Subjects in a Real World Setting | Biotech Hunter | Biotech Hunter